Trial · NCT03068754
Results by group30
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 30
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Treatment Period: Scores on a Scale for Telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) | Arm A: RTP Acthar Gel | Baseline | 34.7 | Standard Deviation 6.01 | score on a scale |
| Treatment Period: Scores on a Scale for Telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) | Arm B: RTP Placebo | Baseline | 34.3 | Standard Deviation 5.84 | score on a scale |
| Treatment Period: Scores on a Scale for Telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) | Arm A: RTP Acthar Gel | Week 36 | 26.4 | Standard Deviation 9.34 | score on a scale |
| Treatment Period: Scores on a Scale for Telephone-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) | Arm B: RTP Placebo | Week 36 | 30.8 | Standard Deviation 7.55 | score on a scale |
| Number of Participants Experiencing an Adverse Event During the Treatment Period | Arm A: RTP Acthar Gel | Serious Treatment Emergent Adverse Events | 13 | Participants | |
| Number of Participants Experiencing an Adverse Event During the Treatment Period | Arm B: RTP Placebo | Serious Treatment Emergent Adverse Events | 6 | Participants | |
| Number of Participants Experiencing an Adverse Event During the Treatment Period | Arm A: RTP Acthar Gel | Non-serious Treatment-Emergent Adverse Events | 74 | Participants | |
| Number of Participants Experiencing an Adverse Event During the Treatment Period | Arm B: RTP Placebo | Non-serious Treatment-Emergent Adverse Events | 40 | Participants | |
| Number of Participants Experiencing an Adverse Event During the Treatment Period | Arm A: RTP Acthar Gel | Death | 2 | Participants | |
| Number of Participants Experiencing an Adverse Event During the Treatment Period | Arm B: RTP Placebo | Death | 3 | Participants | |
| Number of Participants Experiencing an Adverse Event by the End of the Trial in the OLE Period | Arm C: OLE Acthar Gel-Acthar Gel | Serious Treatment Emergent Adverse Events | 4 | Participants | |
| Number of Participants Experiencing an Adverse Event by the End of the Trial in the OLE Period | Arm D: OLE Placebo-Acthar Gel | Serious Treatment Emergent Adverse Events | 2 | Participants | |
| Number of Participants Experiencing an Adverse Event by the End of the Trial in the OLE Period | Arm C: OLE Acthar Gel-Acthar Gel | Non-serious Treatment-Emergent Adverse Events | 20 | Participants | |
| Number of Participants Experiencing an Adverse Event by the End of the Trial in the OLE Period | Arm D: OLE Placebo-Acthar Gel | Non-serious Treatment-Emergent Adverse Events | 7 | Participants | |
| Treatment Period: Spirometry (%) | Arm A: RTP Acthar Gel | FVC at Baseline | 85.0 | Standard Deviation 18.31 | liters |
| Treatment Period: Spirometry (%) | Arm B: RTP Placebo | FVC at Baseline | 82.1 | Standard Deviation 17.60 | liters |
| Treatment Period: Spirometry (%) | Arm A: RTP Acthar Gel | FVC at Week 36 | 61.4 | Standard Deviation 27.37 | liters |
| Treatment Period: Spirometry (%) | Arm B: RTP Placebo | FVC at Week 36 | 63.8 | Standard Deviation 26.05 | liters |
| Treatment Period: Spirometry (%) | Arm A: RTP Acthar Gel | FEV1 at Baseline | 79.3 | Standard Deviation 18.78 | liters |
| Treatment Period: Spirometry (%) | Arm B: RTP Placebo | FEV1 at Baseline | 77.8 | Standard Deviation 18.52 | liters |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03068754/results